In a Healio Video Perspective from Clinical Trials at the Summit, Carolyn Sasse of Astellas discusses the company’s ophthalmology pipeline. She provides updates on post-marketing safety data for Izervay and a phase 1 trial recruiting patients with age-related macular degeneration. Astellas has developed an early-stage pipeline for treating diseases like geographic atrophy, glaucoma, Stargardt, and retinitis pigmentosa with cell and gene therapies. Sasse, the development head of cell and gene therapy at Astellas, highlights the company’s progress in ophthalmology research and development.
Source link
Astellas offers updates on Izervay safety, phase 1 geographic atrophy trial
